Table 2 Outcome data of included studies
From: The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review
Outcome | Hira et al.[36] | Iskandar et al.[33] | Pareek and Chowdhury[35] | Yoon et al.[34] | Lule et al.[28] |
|---|---|---|---|---|---|
Cure | Gentamicin: 98% (216/220) | Gentamicin: 27/30 (90%) | Gentamicin: 19/20 (95%) | Gentamicin: 78/125 (62.4%) | Gentamicin: 38/40 (95%) |
Kanamycin: 95% (85/89) | Co-trimoxazole: 29/30 (96.6%) | Spectinomycin: 16/20 (80%) | Kanamycin: 86/126 (68.3%) | Ciprofloxacin: 55/59 (93%) | |
Lidaprim: 29/30 (96.6%) | 23 patients did not attend follow-up and were excluded | APC: 40/60 (67%) | |||
Adjusted to include only those attending on day 7: | APC-D: 52/56 (93%) | ||||
Gentamicin: 19/22 (86.4%) | Co-trimoxazole: 14/29 (48%) | ||||
Bactrim: 15/16 (93.7%) | |||||
Lidaprim: 20/21(95.2%) | |||||
Need for additional treatment | No data | No data | No data | No data | No data |
Adverse event | ‘No serious toxicity or other adverse reactions were noticed in either group of men. Serum creatinine values were normal in the 52 patients given gentamicin and the 28 kanamycin whose blood samples were tested’ | ‘No adverse side effects were observed in any of the patients’ | ‘There were no obvious side effects with either of these drugs. The blood urea and creatinine values remained within normal limits’ | ‘There was no side effect of using kanamycin and gentamicin’ | No data |
Hospital attendance | No data | No data | No data | No data | No data |